Abeona Therapeutics
$5.64
71
+$0.14+2.49% Hari ini
Statistik
Harga Tertinggi Hari
5.64
Harga Terendah Hari
5.52
52M Tertinggi
8.8
52M Terendah
2.35
Volum
522
Volum Purata
1,007
Kapasiti Pasaran
15.78B
Nisbah P/E
-
Pendapatan Dividen
-
Dividen
-
Akan Datang
Pendapatan
11NovDijangka
EPS yang dijangka
-0.375
EPS sebenar
N/A
Orang Lain Juga Mengikuti
Senarai ini berdasarkan senarai pantau orang di Stock Events yang mengikuti 0H7R.LSE. Ini bukan cadangan pelaburan.
Peserta
Senarai ini adalah analisis berdasarkan peristiwa pasaran terkini. Ini bukan cadangan pelaburan.
Biogen
BIIB
Kapasiti Pasaran29.83B
Pfizer
PFE
Kapasiti Pasaran164.39B
Sangamo Therapeutics
SGMO
Kapasiti Pasaran176.57M
Biomarin Pharmaceutical
BMRN
Kapasiti Pasaran17.36B
Bluebird bio
BLUE
Kapasiti Pasaran108.22M
Ultragenyx Pharmaceutical
RARE
Kapasiti Pasaran5.23B
Sarepta Therapeutics
SRPT
Kapasiti Pasaran12.95B
Vertex Pharmaceuticals
VRTX
Kapasiti Pasaran127.99B
Novo Nordisk
NVO
Kapasiti Pasaran620.4B
Mengenai
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is EB-101, an autologous, engineered cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company develops ABO-503 for the treatment of X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 for the treatment of autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. is headquartered in Cleveland, Ohio.
Show more...
CEO
Dr. Vishwas Seshadri M.B.A., Ph.D.
Pekerja
84
Negara
US
ISIN
US00289Y2063